Kronox Lab Sciences completes 64.26% stake transfer to Indo Borax
- Kronox Lab Sciences completed the transfer of 64.26% equity stake to Indo Borax & Chemicals Ltd on September 29, 2026
- Former promoters are reclassified as public shareholders under SEBI Regulation 31A(10)
- Indo Borax launched an open offer for 25.79% of voting capital from public shareholders
- Board fully reconstituted with Suresh Kalra appointed as new MD and CEO

*this image is generated using AI for illustrative purposes only.
Kronox Lab Sciences Limited announced the completion of the transfer of a 64.26% equity stake to Indo Borax & Chemicals Limited on September 29, 2026. This transaction marks a complete change in control, with the outgoing promoters formally reclassified as public shareholders under SEBI regulations.
The sale involved 2,38,44,000 equity shares held by Mr. Ketan Vinodchandra Ramani, Mr. Pritesh Vinodchandra Ramani, and Mr. Jogindersingh Gianchand Jaswal. Following the transfer, the sellers collectively retain a residual holding of 9.95% in the voting share capital. The deal was executed pursuant to a share purchase agreement signed on August 20, 2026, with Zenrock Chemicals Private Limited also party to the agreement.
Regulatory Reclassification and Open Offer
Pursuant to Regulation 31A(10) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the erstwhile promoter group has ceased to be members of the promoter group. The company confirmed that the sellers do not hold more than 10% of total voting rights, exercise control over affairs, hold special rights, or have representation on the board. Consequently, they are reclassified as public shareholders.
Indo Borax & Chemicals Limited, along with Zenrock Chemicals Private Limited acting in concert, has undertaken an open offer to acquire up to 95,70,000 equity shares, representing 25.79% of the voting share capital, from public shareholders. This open offer is being made in compliance with SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
Board Overhaul and New Leadership
Consequent to the change in control, the entire board structure was reconstituted. The outgoing Managing Director, Mr. Jogindersingh Gianchand Jaswal, resigned immediately, along with executive directors Mr. Ketan Ramani and Mr. Pritesh Vinodchandra Ramani. Additionally, Chief Financial Officer Mr. Samir Gadhiya stepped down from his role as CFO, though he will continue as an employee in senior management.
The new board includes:
- Mr. Suresh Kalra: Appointed as Managing Director and CEO (5-year term).
- Mr. Sunil Malhotra: Appointed as Whole-time Director (5-year term).
- Mr. Harsh Malhotra: Appointed as Executive Director (5-year term).
- Mr. Shashikant Bharuka: Appointed as Chief Financial Officer.
Three new independent directors were also appointed: Mr. Amit Kumar Sharma, Ms. Anuradha Suneet Maheshwari, and Mr. Dhananjay Tapasvi. All three resigning independent directors (Mr. Parth Shah, Ms. Krutika Arunkumar Negandhi, and Mr. Satish Kumar) stepped down simultaneously.
Committee Reconstitution
All statutory committees were reconstituted to reflect the new leadership. Mr. Dhananjay Tapasvi heads the Audit Committee, while Ms. Anuradha Suneet Maheshwari chairs the Stakeholders Relationship Committee. The Nomination and Remuneration Committee is chaired by Mr. Dhananjay Tapasvi.
| Committee | Chairperson | Key Members |
|---|---|---|
| Audit Committee | Mr. Dhananjay Tapasvi | Mr. Suresh Kalra, Mr. Amit Kumar Sharma |
| Nomination & Remuneration | Mr. Dhananjay Tapasvi | Mr. Amit Kumar Sharma, Ms. Anuradha Suneet Maheshwari |
| Stakeholders Relationship | Ms. Anuradha Suneet Maheshwari | Mr. Suresh Kalra, Mr. Harsh Malhotra |
| CSR Committee | Mr. Suresh Kalra | Ms. Anuradha Suneet Maheshwari, Mr. Sunil Malhotra |
Transition Support Agreements
To ensure operational continuity, the company entered into consultancy agreements with the three former promoters. Each agreement is for a period of 36 months with a fixed aggregate fee of ₹2.10 crore per consultant. These agreements cover transition support for research, development, production, and quality assurance, including oversight of the proposed manufacturing facility at GIDC, Dahej-II.
What the Numbers Show
The transaction highlights a clean exit strategy where former promoters retain a minority stake (9.95%) while securing substantial consultancy fees (₹6.30 crore aggregate) for a three-year transition period. This structure suggests that while Indo Borax assumes full governance control, it relies on the technical expertise of the founding family for operational stability during the critical post-acquisition phase.
Historical Stock Returns for Kronox Lab Sciences
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.06% | +22.86% | +20.85% | +112.97% | +33.90% | +36.23% |
How will Indo Borax & Chemicals integrate Kronox's existing product lines into its current portfolio to drive immediate revenue synergies?
What specific strategic milestones are outlined for the proposed GIDC Dahej-II manufacturing facility under the new leadership's 5-year roadmap?
What is the expected timeline and likely outcome of the open offer for the remaining 25.79% voting share capital?


































